

wherein R^5 and R^6 are each independently selected from the group consisting of $-OC(O)OCH_3$, -OH, -SH, $-NH_2$,$-OSO_3H$, $-OPO_3H$, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer, provided that at least one of R^5 and R^6 are $-OC(O)OCH_3$;

wherein R^7, R^8, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18} and R^{19} are each independently selected from the group consisting of -H, -OH, -SH, $-NH_2$,$-OSO_3H$, $-OPO_3H$, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer and R^7 and R^8 together, R^{12} and R^{13} together, R^{14} and R^{15}

B cont'd

together, R^{16} and R^{17} together, and R^{18} and R^{19} together independently form a double bond to a moiety selected from the group consisting of =O, =S, $=CH_2$ and =NOH, provided that only one each of R^{12} and R^{13} or R^{18} and R^{19} can independently be -H;
wherein R^{24} and R^{25} are either -H or $-CH_3$;
wherein the dotted line is an optional double bond;
wherein the $-OC(O)OCH_3$ at the 3 position is in either the α or β configuration;
and a pharmaceutically acceptable excipient.

34. (New) The pharmaceutical composition of claim 33, wherein said at least one compound has the following structure



wherein R^7, R^8, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18} and R^{19} are each independently selected from the group consisting of -H, -OH, -SH, $-NH_2$, $-OSO_3H$, $-OPO_3H$, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer and R^7 and R^8 together, R^{12} and R^{13} together, R^{14} and R^{15}

together, R^{16} and R^{17} together, and R^{18} and R^{19} together independently form a double bond to a moiety selected from the group consisting of =O, =S, $=CH_2$ and =NOH, provided that only one each of R^{12} and R^{13} or R^{18} and R^{19} can independently be -H;
wherein R^{24} and R^{25} are either -H or $-CH_3$;
wherein the dotted line is an optional double bond;
wherein the $-OC(O)OCH_3$ at the 3 position is in either the α or β configuration;
and a pharmaceutically acceptable excipient.

35. (New) The pharmaceutical composition of claim 34, wherein said at least one compound has the following structure



wherein R^7, R^8, R^{12}, R^{13}, R^{14}, R^{15}, R^{16} and R^{17} are each independently selected from the group consisting of -H, -OH, -SH, $-NH_2$, $-OSO_3H$, $-OPO_3H$, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer and R^7 and R^8 together, R^{12} and R^{13} together, R^{14} and R^{15} together, and R^{16} and R^{17} together independently form a double bond to a moiety

selected from the group consisting of =O, =S, $=CH_2$ and =NOH, provided that only one of each of R^{12} and R^{13} can independently be -H;

wherein R^{24} and R^{25} are either -H or $-CH_3$;

wherein the dotted line is an optional double bond;

wherein the $-OC(O)OCH_3$ at the 3 position is in either the α or β configuration;

and a pharmaceutically acceptable excipient.

36. (New) The pharmaceutical composition of claim 35, wherein said at least one compound has the following structure



,

wherein R^{12} and R^{13} are each independently selected from the group consisting of -H, -OH, -SH, $-NH_2$, $-OSO_3H$, $-OPO_3H$, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer and R^{12} and R^{13} together form a double bond to a moiety selected from the group consisting of =O, =S, $=CH_2$ and =NOH, provided that only one of R^{12} and R^{13} is -H;

wherein R^{24} and R^{25} are either -H or $-CH_3$;

wherein the dotted line is an optional double bond;

wherein the $-OC(O)OCH_3$ at the 3 position is in either the α or β configuration;
and a pharmaceutically acceptable excipient.

37. (New) The pharmaceutical composition of claim 34, wherein said at least one compound has the following structure



wherein R^7, R^8, R^{14}, R^{15}, R^{16}, R^{17}, R^{18} and R^{19} are each independently selected from the group consisting of -H, -OH, -SH, $-NH_2$, $-OSO_3H$, $-OPO_3H$, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer and R^7 and R^8 together, R^{14} and R^{15} together, R^{16} and R^{17} together, and R^{18} and R^{19} together independently form a double bond to a moiety selected from the group consisting of =O, =S, $=CH_2$ and =NOH, provided that only one of each of R^{18} and R^{19} can be -H;
wherein R^{24} and R^{25} are either -H or $-CH_3$;
wherein the dotted line is an optional double bond;

B' cont'd

wherein the $-OC(O)OCH_3$ at the 3 position is in either the α or β configuration;
and a pharmaceutically acceptable excipient.

38. (New) The pharmaceutical composition of claim 37, wherein said at least one compound has the following structure



,

wherein R^{18} and R^{19} are each independently selected from the group consisting of -H, -OH, -SH, $-NH_2$,$-OSO_3H$, $-OPO_3H$, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer and R^{18} and R^{19} together form a double bond to a moiety selected from the group consisting of =O, =S, $=CH_2$ and =NOH, provided that only one of R^{18} and R^{19} is -H;
wherein R^{24} and R^{25} are either -H or $-CH_3$;
wherein the dotted line is an optional double bond;
wherein the $-OC(O)OCH_3$ at the 3 position is in either the α or β configuration;
and a pharmaceutically acceptable excipient.

39. (New) The pharmaceutical composition of claim 34, wherein said at least one compound has the following structure



and a pharmaceutically acceptable excipient.

40. (New) A method to treat or prevent an androgen responsive disease in a subject, or to ameliorate one or more symptoms thereof, comprising administering to the subject, or delivering to the subject's tissues, an effective amount of the pharmaceutical composition of claim 33.

B1 cont'd

41. (New) The method of claim 40, wherein the androgen responsive disease is selected from the group consisting of prostate cancer, benign prostatic hyperplasia, breast cancer, alopecia, acne, hypogonadism and hirsutism.

42. (New) A method to treat or prevent an androgen responsive disease in a subject, or to ameliorate one or more symptoms thereof, comprising administering to the subject, or delivering to the subject's tissues, an effective amount of the pharmaceutical composition of claim 34.

43. (New) The method of claim 42, wherein the androgen responsive disease is selected from the group consisting of prostate cancer, benign prostatic hyperplasia, breast cancer, alopecia, acne, hypogonadism and hirsutism.

44. (New) A method to treat or prevent an androgen responsive disease in a subject, or to ameliorate one or more symptoms thereof, comprising administering to the subject, or delivering to the subject's tissues, an effective amount of the pharmaceutical composition of claim 35.

45. (New) The method of claim 44, wherein the androgen responsive disease is selected from the group consisting of prostate cancer, benign prostatic hyperplasia, breast cancer, alopecia, acne, hypogonadism and hirsutism.

46. (New) A method to treat or prevent an androgen responsive disease in a subject, or to ameliorate one or more symptoms thereof, comprising administering to the subject, or delivering to the subject's tissues, an effective amount of the pharmaceutical composition of claim 36.

B1 cont'd

47. (New) The method of claim 46, wherein the androgen responsive disease is selected from the group consisting of prostate cancer, benign prostatic hyperplasia, breast cancer, alopecia, acne, hypogonadism and hirsutism.

48. (New) A method to treat or prevent an androgen responsive disease in a subject, or to ameliorate one or more symptoms thereof, comprising administering to the subject, or delivering to the subject's tissues, an effective amount of the pharmaceutical composition of claim 37.

49. (New) The method of claim 48, wherein the androgen responsive disease is selected from the group consisting of prostate cancer, benign prostatic hyperplasia, breast cancer, alopecia, acne, hypogonadism and hirsutism.

50. A method to treat or prevent an androgen responsive disease in a subject, or to ameliorate one or more symptoms thereof,